Blow to Biogen as ALS hope tofersen flunks phase 3 trialAlready struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback Share XBlow to Biogen as ALS hope tofersen flunks phase 3 trialhttps://pharmaphorum.com/news/blow-to-biogen-as-als-hope-tofersen-flunks-phase-3-trial/
Bad news for Biohaven as verdiperstat flunks first phase 3 testBiohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological Share XBad news for Biohaven as verdiperstat flunks first phase 3 testhttps://pharmaphorum.com/news/bad-news-for-biohaven-as-verdiperstat-flunks-first-phase-3-test/
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialIt has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new Share XAZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialhttps://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseasesIpsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took Share XIpsen forges $1bn alliance with Exicure on neurodegenerative diseaseshttps://pharmaphorum.com/news/ipsen-forges-1bn-alliance-with-exicure-on-neurodegenerative-diseases/
Healx deploys its AI in hunt for Friedreich’s ataxia therapiesUK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new Share XHealx deploys its AI in hunt for Friedreich’s ataxia therapieshttps://pharmaphorum.com/news/healx-deploys-its-ai-in-hunt-for-friedreichs-ataxia-therapies/
AI drug discovery firm Valence joins Parkinson’s disease pushCanada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat Share XAI drug discovery firm Valence joins Parkinson’s disease pushhttps://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/
Biotech trends in COVID era: the pharmaphorum podcastIn episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently Share XBiotech trends in COVID era: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/biotech-trends-pharnext-david-solomon/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
Evotec and Celgene unite to drive forward oncology R&DEvotec and Celgene have joined forces in a long-term strategic drug discovery and development partnership, to identify new Share XEvotec and Celgene unite to drive forward oncology R&Dhttps://pharmaphorum.com/news/evotec-celgene-unite-drive-forward-oncology-rd/
